ASH Preview: J&J And Legend’s CAR-T Takes Center Stage
Frontrunners Bide Their Time
Executive Summary
While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.
You may also be interested in...
DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma
The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.
Sanofi Myeloma Drug Shines But Darzalex Dominates Still
While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.